Relationship between therapeutic efficacy of doxorubicin-transferrin conjugate and expression of P-glycoprotein in chronic erythromyeloblastoid leukemia cells sensitive and resistant to doxorubicin
| dc.contributor.author | Szwed, Marzena | |
| dc.contributor.author | Kania, Katarzyna D. | |
| dc.contributor.author | Jozwiak, Zofia | |
| dc.date.accessioned | 2015-06-17T11:22:35Z | |
| dc.date.available | 2015-06-17T11:22:35Z | |
| dc.date.issued | 2014-11-20 | |
| dc.identifier.issn | 2211-3436 | |
| dc.identifier.uri | http://hdl.handle.net/11089/9915 | |
| dc.description.abstract | Background Conjugation of anti-neoplastic agents with human proteins is a strategy to diminish the toxic side effects of anthracycline antibiotics. We have developed a novel doxorubicin-transferrin (DOX-TRF) conjugate aimed to direct anticancer drugs against therapeutic targets that display altered levels of expression in malignant versus normal cells. Our previous work has shown that the cellular bio-distribution of the conjugate is dependent on a dynamic balance between influx and efflux processes. Here, we set out to investigate whether P-glycoprotein (P-gp) expression may affect DOXTRF conjugate-induced cellular drug accumulation and cytotoxicity. Results All experiments were carried out on human erythromyeloblastoid cells exhibiting P-gp over-expression (K562/DOX) and its drug sensitive parental line (K562). MTT cytotoxicity, flow cytometry, fluorescence microscopy and RT-PCR assessments revealed that the investigated conjugate (DOX-TRF) possesses a greater cytotoxic potential than free DOX. Conclusion Our data suggest that the newly developed DOXTRF conjugate is a less P-gp dependent substrate than free DOX and, consequently, may be used in a clinical setting to increase treatment efficacy in resistant human tumors. | pl_PL |
| dc.description.sponsorship | Grant no. 545/ 756 of the University of Lodz, Poland. | pl_PL |
| dc.language.iso | en | pl_PL |
| dc.publisher | International Society for Cellular Oncology, IOS Press | pl_PL |
| dc.relation.ispartofseries | Cell Oncology (Dordrecht);(2014) 37 | |
| dc.rights | Uznanie autorstwa 3.0 Polska | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/pl/ | * |
| dc.subject | Doxorubicin | pl_PL |
| dc.subject | Transferrin | pl_PL |
| dc.subject | Drug carriers | pl_PL |
| dc.subject | Multidrug resistance | pl_PL |
| dc.subject | P-glycoprotein | pl_PL |
| dc.title | Relationship between therapeutic efficacy of doxorubicin-transferrin conjugate and expression of P-glycoprotein in chronic erythromyeloblastoid leukemia cells sensitive and resistant to doxorubicin | pl_PL |
| dc.type | Article | pl_PL |
| dc.page.number | 421–428 | pl_PL |
| dc.contributor.authorAffiliation | Szwed Marzena, University of Lodz, Department of Thermobiology, Faculty of Biology and Environmental Protection, | pl_PL |
| dc.contributor.authorAffiliation | Kania Katarzyna D., Institute for Medical Biology, Laboratory of Transcriptional Regulation. | pl_PL |
| dc.contributor.authorAffiliation | Jozwiak Zofia, University of Lodz, Department of Thermobiology, Faculty of Biology and Environmental Protection. | pl_PL |
| dc.references | B. Ríhová, J. Strohalm, O. Hovorka, V. Subr, T. Etrych, P. Chytil, R. Pola, D. Plocová, J. Boucek, K. Ulbrich, Doxorubicin release is not a prerequisite for the in vitro cytotoxicity of HPMA-based pharmaceuticals: in vitro effect of extra drug-free GlyPheLeuGly sequences. J. Control. Release 127, 110–120 (2008) | pl_PL |
| dc.references | M.Mazevet, M.Moulin,A. Llach-Martinez, C. Chargari, E.Deutsch, A.M. Gomez, E. Morel, Complications of chemotherapy, a basic science update. Presse Med. 42, e352–e361 (2013) | pl_PL |
| dc.references | K.J. Patel, O. Trédan, I.F. Tannock, Distribution of the anticancer drugs doxorubicin,mitoxantrone and topotecan in tumors and normal tissues. Cancer Chemother. Pharmacol. 72, 127–138 (2013) | pl_PL |
| dc.references | C. Mamot, R. Ritschard, A. Wicki, G. Stehle, T. Dieterle, L. Bubendorf, C. Hilker, S. Deuster, R. Herrmann, C. Rochlitz, Tolerability, safety, pharmacokinetics, and efficacy of doxorubicinloaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. Lancet Oncol. 13, 1234–1241 (2012) | pl_PL |
| dc.references | B. Ky, P. Vejpongsa, E.T. Yeh, T. Force, J.J. Moslehi, Emerging paradigms in cardiomyopathies associated with cancer therapies. Circ. Res. 113, 754–764 (2013) | pl_PL |
| dc.references | P.S. Guerreiro, A.S. Fernandes, J.G. Costa, M. Castro, J.P. Miranda, N.G. Oliveira, Differential effects of methoxyamine on doxorubicin cytotoxicity and genotoxicity inMDA-MB-231 human breast cancer cells. Mut Res. 757, 140–147 (2013) | pl_PL |
| dc.references | S. Aroui, S. Brahim, M.D. Waard, A. Kenani, Cytotoxicity, intracellular distribution and uptake of doxorubicin and doxorubicin coupled to cell-penetrating peptides in different cell lines: a comparative study. Biochem Biophys Res Comm. 391, 419–425 (2010) | pl_PL |
| dc.references | C.Y. Quan, C. Chang, H.Wei, C.S. Chen, X.D. Xu, S.X. Cheng, X.Z. Zhang, R.X. Zhuo, Dual targeting of a thermo sensitive nanogel conjugated with transferrin and RGD-containing peptide for effective cell uptake and drug release. Nanotechnology 20, 335101 (2009) | pl_PL |
| dc.references | F. Kratz, Acid-sensitive prodrugs of doxorubicin. Top. Curr. Chem. 283, 73–97 (2008) | pl_PL |
| dc.references | L.W. Seymour, Passive tumor targeting of soluble macromolecules and drug conjugates. Crit. Rev. Ther. Drug Carrier Syst. 9, 135–187 (1992) | pl_PL |
| dc.references | F. Yuan, M. Dellian, D. Fukumura, M. Leunig, D.A. Berk, V.P. Torchilin, R.K. Jain, Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55, 3752–3756 (1995) | pl_PL |
| dc.references | F. Kratz, U. Beyer, T. Roth, N. Tarasova, P. Collery, F. Lechenault, A. Cazabat, P. Schumacher, C. Unger, U. Falken, Transferrin conjugates of doxorubicin: synthesis, characterization, cellular uptake, and in vitro efficacy. J. Pharm. Sci. 87, 338–346 (1998) | pl_PL |
| dc.references | H.C. Arora,M.P. Jensen, Y. Yuan, A.Wu, S. Vogt, T. Paunesku, G.E. Woloschak, Nanocarriers enhance doxorubicin uptake in drugresistant ovarian cancer cells. Cancer Res. 72, 769–778 (2012) | pl_PL |
| dc.references | A. Saneja, V. Khare, N. Alam, R.D. Dubey, P.N. Gupta, Advances in P-glycoprotein-based approaches for delivering anticancer drugs: pharmacokinetic perspective and clinical relevance. Expert Opin Drug Deliv. 11, 121–138 (2014) | pl_PL |
| dc.references | A.A. Kovalev, D.A. Tsvetaeva, T.V. Grudinskaja, Role of ABCcassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer. Exp. Oncol. 35, 287–290 (2013) | pl_PL |
| dc.references | B. Bauer, A.M. Hartz, G. Fricker, D.S. Miller, Modulation of pglycoprotein transport function at the blood–brain barrier. Exp Biol Med. 230, 118–127 (2005) | pl_PL |
| dc.references | B. LZ, The drug transporter-metabolism alliance: uncovering and defining the interplay. Mol. Pharm. 6, 1631–1643 (2009) | pl_PL |
| dc.references | C. Bosquillon, Drug transporters in the lung-implication in the biopharmaceutics of inhaled drugs. J. Pharm. Sci. 99, 2240–2255 (2009) | pl_PL |
| dc.references | S. Endter, U. Becker, N. Daum, H. Huwer, C.M. Lehr,M. Gumbleton, C. Ehrhardt, P-glycoprotein (MDR1) functional activity in human alveolar epithelial cell monolayers. Cell Tissue Res. 328, 77–84 (2007) | pl_PL |
| dc.references | F.J. Sharom, Complex Interplay between the P-Glycoprotein Multidrug Efflux Pump and the Membrane: Its Role in Modulating Protein Function. Front Oncol (2014). doi:10.3389/fonc.2014.00041 | pl_PL |
| dc.references | A. Berczi, M. Ruthner, V. Szuts, M. Fritzer, E. Schweizner, H. Goldenberg, Influence of conjugation of doxorubicin to transferrin on the iron uptake by K562 cells via receptor-mediated endocytosis. Eur J Bioch. 213, 427–436 (1993) | pl_PL |
| dc.references | M. Szwed, A. Matusiak, A. Laroche-Clary, J. Robert, I. Marszalek, Z. Jozwiak, Transferrin as a drug carrier: cytotoxicity, cellular uptake and transport kinetics of doxorubicin transferrin conjugate in the human leukemia cells. Toxicol In Vitro. 28, 187–197 (2014) | pl_PL |
| dc.references | T. Ikegawa, F. Ushigome, N. Koyabu, S.Morimoto, Y. Shoyama, M. Naito, T. Tsuruo, H. Ohtani, Y. Sawada, Inhibition of P-glycoprotein by orange juice components, polymethoxy flavones in adriamycinresistant human myelogenous leukemia (K562/ADM) cells. Cancer Lett. 160, 21–28 (2000) | pl_PL |
| dc.references | Y. Zhou, M.M. Gottesman, I. Pastan, The extracellular loop between TM5 and TM6 of P-glycoprotein is required for reactivity with monoclonal antibody UIC2. Arch. Biochem. Biophys. 1, 74–80 (1999) | pl_PL |
| dc.references | R. Gondko, A. Zgirski, M. Adamska, Biostatistics in tasks, 3rd edn. (University of Lodz, Lodz, 2011), pp. 135–141 | pl_PL |
| dc.references | G. Lehne, D.R. Sørensen, G.E. Tjønnfjord, C. Beiske, T.A. Hagve, H.E. Rugstad, O.P. Clausen, The cyclosporin PSC 833 increases survival and delays engraftment of human multidrug-resistant leukemia cells in xenotransplanted NOD-SCID mice. Leukemia 16, 2388– 2394 (2002) | pl_PL |
| dc.references | M.R. Grey, R. Burgess, A. Fisher, J.A. Yin, Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in chronic lymphocytic leukaemia. Leuk. Res. 23, 29–35 (1999) | pl_PL |
| dc.references | S. Lo, B. Tolner, J.W. Taanman, J.M. Cooper, M. Gu, J.A. Hartley, A.H. Schapira, D. Hochhauser, Assessment of the significance of mitochondrial DNA damage by chemotherapeutic agents. Int. J. Oncol. 27, 337–344 (2005) | pl_PL |
| dc.references | P.S. Lai, C.L. Pai, C.L. Peng, M.J. Shieh, K. Berg, P.J. Lou, Enhanced cytotoxicity of saporin by polyamidoamine dendrimer conjugation and photochemical internalization. J Biomed Mater Res. A 87, 147–155 (2008) | pl_PL |
| dc.references | M.J. Shieh, C.L. Peng, P.J. Lou, C.H. Chiu, T.Y. Tsai, C.Y. Hsu, C.Y. Yeh, P.S. Lai, Nontoxic photo-triggered gene transfection by PAMAM–porphyrin conjugates. J. Drug Target. 15, 279–284 (2007) | pl_PL |
| dc.references | J.J. Yu, H.A. Lee, J.H. Kim, W.H. Kong, Y. Kim, Z.Y. Cui, K.G. Park,W.S. Kim, H.G. Lee, S.W. Seo, Bio-distribution and anti-tumor efficacy of PEG/PLA nanoparticles loaded doxorubicin. J. Drug Target. 15, 279–284 (2007) | pl_PL |
| dc.references | J.C. Wang, B. Goh, W.L. Lu, Q. Zhang, A. Chang, X.Y. Liu, T.M. Tan, H. Lee, In vitro cytotoxicity of stealth liposomes coencapsulating doxorubicin and verapamil on doxorubicin-resistant tumor cells. Biol. Pharm. Bull. 28, 822–828 (2005) | pl_PL |
| dc.references | H.L.Wong, R. Bendayan, A.M. Rauth, X.Y.Wu,Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers. J. Pharm. Sci. 93, 1993–2008 (2004) | pl_PL |
| dc.references | J.Wu, Y. Lu, A. Lee, X. Pan, X. Yang, X. Zhao, R.J. Lee, Reversal of multidrug resistance by transferrin-conjugated liposomes coencapsulating doxorubicin and verapamil. J. Pharm. Pharm. Sci. 10, 350–357 (2007) | pl_PL |
| dc.references | C. Mamot, D.C. Drummond, K. Hong, D.B. Kirpotin, J.W. Park, Liposome-based approaches to overcome anticancer drug resistance. Drug Resis Updates. 6, 271–279 (2003) | pl_PL |
| dc.references | K. Zhang, W. Chen, T. Bu, H. Qi, R. Sun, X. He, Decreased Pglycoprotein is associated with the inhibitory effects of static magnetic fields and cisplatin on K562 cells. Bioelectromagnetics 35, 437–443 (2014) | pl_PL |
| dc.contributor.authorEmail | szwedma@biol.uni.lodz.pl | pl_PL |
Pliki tej pozycji
Pozycja umieszczona jest w następujących kolekcjach
Poza zaznaczonymi wyjątkami, licencja tej pozycji opisana jest jako Uznanie autorstwa 3.0 Polska